79,848 Shares in Twist Bioscience Corporation $TWST Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 79,848 shares of the company’s stock, valued at approximately $8,215,000.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Twist Bioscience in the 2nd quarter worth about $600,191,000. William Blair Investment Management LLC bought a new stake in Twist Bioscience during the second quarter worth about $223,722,000. EdgePoint Investment Group Inc. boosted its stake in Twist Bioscience by 31.7% during the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after acquiring an additional 1,295,672 shares in the last quarter. Millennium Management LLC grew its holdings in Twist Bioscience by 151.5% in the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after purchasing an additional 1,080,722 shares during the period. Finally, ARK Investment Management LLC increased its stake in shares of Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after purchasing an additional 832,687 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, SVP Paula Green sold 291 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the transaction, the senior vice president owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. This trade represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 41,570 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the sale, the chief executive officer owned 770,729 shares of the company’s stock, valued at $117,135,393.42. This trade represents a 5.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 193,099 shares of company stock worth $24,026,581 over the last 90 days. 3.08% of the stock is owned by company insiders.

Twist Bioscience Stock Performance

Shares of TWST opened at $141.38 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $155.44. The firm has a market capitalization of $8.87 billion, a P/E ratio of -63.68 and a beta of 2.14. The business has a fifty day moving average of $106.95 and a 200 day moving average of $74.01.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.33 EPS. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Barclays lifted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Canaccord Genuity Group lifted their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. UBS Group set a $89.00 target price on Twist Bioscience in a report on Monday, June 15th. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Finally, Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $98.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.